"id:ID","studyEstimands","studyInvestigationalInterventions","description","studyDesignRationale","uuid","label","documentVersion","id","bcCategories","name"
"820","[]","[]","The main design for the study","The discontinuation rate associated with this oral dosing regimen was 58.6% in previous studies, and alternative clinical strategies have been sought to improve tolerance for the compound. To that end, development of a Transdermal Therapeutic System (TTS) has been initiated.","1ee7ee3b-b6c7-4da2-8529-e5f90787a990","","","StudyDesign_1","[]","Study Design 1"
